Navigation Links
Newest Coated Stent Does Well in Real-World Trial
Date:6/17/2009

Safe and effective in an 'all-comer population,' researchers say

WEDNESDAY, June 17 (HealthDay News) -- The newest drug-coated stent has performed well in a real-life trial, Dutch cardiologists report.

The Xience stent -- a flexible metal-mesh tube coated with the drug everolimus -- is inserted to keep blood flowing after artery-opening procedures such as angioplasty, and is already in widespread use. It was approved by the U.S. Food and Drug Administration last July, on the basis of good results in controlled trials.

But those trials included only people with simple artery blockages and the effectiveness of the new stent in "complex, unselected patients treated in daily practice still remains unknown and cannot be extrapolated from these randomized controlled trials," said cardiologists at Erasmus Medical Center in Rotterdam in their report, which was released online June 17 in advance of publication in the Journal of the American College of Cardiology. "We therefore sought to evaluate the impact of this second-generation drug-eluting stent on the clinical outcomes in consecutive patients treated in a real-life, all-comer population."

The trial compared the outcomes of 649 people given Xience stents with individuals who previously had stents implanted -- 450 with bare-metal stents, 508 with stents coated with the drug sirolimus and 576 with stents coated with the drug paclitaxel. The data include people with multiple artery blockages and some treated after heart attacks.

In the cautious phrasing of the Rotterdam group, "this study suggests that the use of everolimus-eluting stents in an unselected population may be as safe as and more effective than bare-metal stents, may be as safe and effective as sirolimus-eluting stents, may be as safe as paclitaxel-eluting stents, and may be more effective than paclitaxel-eluting stents."

Specifically, in a six-month follow-up period, the incidence of death, heart attack and stenosis (new blockage of the artery) was lower for the Xience group than for those with bare-metal stents and slightly better than those with first-generation drug-eluting stents.

This is good news, said Dr. Gregg W. Stone, an interventional cardiologist who is a professor of medicine at Columbia University and who took part in the controlled trials that led to FDA approval of Xience.

"This more real-world experience is reassuring," Stone said. But additional studies are needed because "the patient size in this trial was small, and it is more difficult to draw conclusions from non-randomized trials," Stone explained.

Nevertheless, the American cardiology community appears to have drawn its own conclusions already, Stone said. Drug-coated stents now are used in about 75 percent of cases, and the Xience stent is used in "50 to 60 percent of that 75 percent," he said.

Everolimus is a more potent drug than those used in the first-generation coated stents and also is contained in a thin, inert polymer that is less likely to cause inflammation, Stone said. The Xience stent itself is also thinner than the previous devices, he added.

"This is a good step forward on evaluating the next generation of drug-eluting stents," said Dr. Manesh Patel, director of the catheterization research laboratory at Duke University.

"The data I see from the [new study] is reassuring," Patel said. "If you are a patient who is being evaluated and a stent is being considered for your coronary, this stent looks safe for at least six months."

Longer follow-up data on more recipients is needed, he noted. Abbott Vascular, which markets the Xience V stent, is sponsoring a data bank that already has information on 5,000 recipients, Patel said.

Stent research and development continues, Stone stated. A stent with a bioabsorbable polymer that disappears is being tested, and further down the road is a stent that itself would dissolve over time, he said.

More information

The why and how of stents are explained by the U.S. National Library of Medicine.



SOURCES: Gregg W. Stone, M.D., professor, medicine, Columbia University, New York City; Manesh Patel, M.D., associate professor, medicine, Duke University, Durham, N.C.; June 17, 2009, Journal of the American College of Cardiology, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making
2. Carefxs Newest White Paper Illuminates Healthcare CIOs Growing Role in Operations, Strategic Thinking and IT Project Decision Making
3. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
4. German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAKs CRO Connect Program(TM)
5. L.A.s Newest Advanced Imaging Center Houses New GE 64-Slice PET/CT and 3T MRI in Spa-Inspired Environment
6. Stratus Technologies Signs Allen Technologies as Newest Channel Partner for High Availability Avance Software
7. SafetyTies Keep Getting Safer: Newest Neckties Reduce the Spread of Germs and Stylishly Feature the Microbes They Fight
8. Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast
9. ALDO Supports World AIDS Day by Donating 100% of Proceeds for Newest ALDO Fights Aids Product
10. MedVantx(R) Names Newest Board Member
11. Mens Health Network Welcomes its Newest Member to its Nationwide Team, The Sean Kimerling Testicular Cancer Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newest Coated Stent Does Well in Real-World Trial
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... combining seaweeds, botanicals and 100 percent pure essential oils, announced the company had a ... Head, SC. , The annual ECRM event gives companies that work in the nutritional, ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... ... Angel”: a heartwarming and earnest tale of faith and believing in the path ... the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of The ... of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, but ...
(Date:1/20/2017)... ... 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the true ... mother of three in Oklahoma City, and a devoted woman of faith. , “Becoming ... been in the back of my mind for years, but actually doing it might have ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 The global immunomodulators ... by 2025, according to a new study by ... to be predominantly driven by high R&D investments ... large-scale production of new and therapeutically advanced drugs. ... drugs at an unprecedented rate into the immunomodulators ...
(Date:1/19/2017)... 19, 2017 The Global Therapy Partnering Terms ... to partnering deals and agreements entered into by the ... deals - Top deals by value - Deals listed ... type The report provides understanding and access to ... world,s leading healthcare companies. The report provides an ...
(Date:1/19/2017)... WASHINGTON , Jan. 19, 2017 Conference Call and ... VNDA ) today announced it will release results for the ... market closes. ... Vanda will host a conference call at 4:30 PM ET on ... quarter and full year 2016 financial results and other corporate activities. ...
Breaking Medicine Technology: